Citius Pharmaceuticals Inc
CTXR1.350USD
+0.060+4.65%
交易中 （美东）报价延迟15分钟
11.83M总市值
亏损市盈率 TTM
关于 Citius Pharmaceuticals Inc 公司
Citius Pharmaceuticals, Inc. 是一家专注于开发和商业化一流重症监护产品的生物制药公司，拥有一系列抗感染药物，包括肿瘤抗感染药物、辅助癌症治疗药物、干细胞治疗药物和处方药物。该公司经 FDA 批准的 LYMPHIR 候选药物是一种靶向免疫疗法，初步适应症为治疗皮肤 T 细胞淋巴瘤。其后期研发管线还包括 Mino-Lok 和 CITI-002 (Halo-Lido)。Mino-Lok 是一种抗生素封管液，用于治疗导管相关血流感染 (CRBSI) 和中心静脉导管相关血流感染 (CLABSI) 患者。Halo-Lido 是丙酸卤倍他索、皮质类固醇和利多卡因的外用制剂，用于治疗痔疮。该公司还正在寻求开发和商业化 NoveCite 间充质干细胞 (NC-iMSC)，以治疗急性呼吸系统疾病，近期重点关注 ARDS。
公司简介
公司代码CTXR
公司名称Citius Pharmaceuticals Inc
上市日期Aug 03, 2017
CEOMr. Leonard L. Mazur
员工数量23
证券类型Ordinary Share
年结日Aug 03
公司地址11 Commerce Dr Fl 1
城市CRANFORD
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编07016-3501
电话19089676677
网址https://www.citiuspharma.com/
公司代码CTXR
上市日期Aug 03, 2017
CEOMr. Leonard L. Mazur
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Leonard L. Mazur
Mr. Leonard L. Mazur
Executive Chairman of the Board, Chief Executive Officer, Company Secretary
Executive Chairman of the Board, Chief Executive Officer, Company Secretary
410.21K
--
Mr. Myron Z. Holubiak
Mr. Myron Z. Holubiak
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
79.69K
--
Mr. Jaime Bartushak
Mr. Jaime Bartushak
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
2.41K
--
Ms. Carol A. Webb
Ms. Carol A. Webb
Independent Director
Independent Director
473.00
--
Mr. Suren G. Dutia
Mr. Suren G. Dutia
Independent Director
Independent Director
--
--
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
Independent Director
Independent Director
--
--
Mr. Robert Smith
Mr. Robert Smith
Independent Director
Independent Director
--
--
Dr. Eugene Holuka, M.D.
Dr. Eugene Holuka, M.D.
Independent Director
Independent Director
--
--
Dr. Myron S. Czuczman, M.D.
Dr. Myron S. Czuczman, M.D.
Chief Medical Officer, Executive Vice President
Chief Medical Officer, Executive Vice President
--
--
Ms. Ilanit Allen
Ms. Ilanit Allen
Vice President - Corporate Communications and Investor Relations
Vice President - Corporate Communications and Investor Relations
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Leonard L. Mazur
Mr. Leonard L. Mazur
Executive Chairman of the Board, Chief Executive Officer, Company Secretary
Executive Chairman of the Board, Chief Executive Officer, Company Secretary
410.21K
--
Mr. Myron Z. Holubiak
Mr. Myron Z. Holubiak
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
79.69K
--
Mr. Jaime Bartushak
Mr. Jaime Bartushak
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
2.41K
--
Ms. Carol A. Webb
Ms. Carol A. Webb
Independent Director
Independent Director
473.00
--
Mr. Suren G. Dutia
Mr. Suren G. Dutia
Independent Director
Independent Director
--
--
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月1日 周五
更新时间: 8月1日 周五
持股股东
股东类型
持股股东
持股股东
占比
Mazur (Leonard L)
3.67%
The Vanguard Group, Inc.
2.31%
Cambridge Investment Research Advisors, Inc.
1.64%
Geode Capital Management, L.L.C.
0.80%
Holubiak (Myron Z)
0.71%
Other
90.87%
持股股东
持股股东
占比
Mazur (Leonard L)
3.67%
The Vanguard Group, Inc.
2.31%
Cambridge Investment Research Advisors, Inc.
1.64%
Geode Capital Management, L.L.C.
0.80%
Holubiak (Myron Z)
0.71%
Other
90.87%
股东类型
持股股东
占比
Individual Investor
4.41%
Investment Advisor
3.85%
Investment Advisor/Hedge Fund
1.67%
Family Office
0.06%
Research Firm
0.06%
Hedge Fund
0.04%
Other
89.91%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
165
1.31M
11.73%
-353.64K
2025Q1
169
1.13M
11.42%
-544.10K
2024Q4
168
1.14M
14.47%
-515.44K
2024Q3
169
1.44M
20.81%
-417.96K
2024Q2
172
1.73M
24.82%
+70.78K
2024Q1
173
1.58M
24.88%
-79.28K
2023Q4
174
1.58M
25.44%
+2.32K
2023Q3
176
1.59M
25.85%
-262.33K
2023Q2
182
1.61M
27.57%
+189.02K
2023Q1
176
1.17M
20.04%
-306.38K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Mazur (Leonard L)
410.21K
3.67%
--
--
Apr 18, 2025
The Vanguard Group, Inc.
257.63K
2.31%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
89.28K
0.8%
+12.77K
+16.69%
Mar 31, 2025
Holubiak (Myron Z)
79.69K
0.71%
--
--
Apr 18, 2025
BlackRock Institutional Trust Company, N.A.
72.23K
0.65%
--
--
Mar 31, 2025
UBS Financial Services, Inc.
66.86K
0.6%
+39.65K
+145.67%
Mar 31, 2025
Squarepoint Capital LLP
60.98K
0.55%
+11.31K
+22.78%
Mar 31, 2025
State Street Global Advisors (US)
23.27K
0.21%
--
--
Mar 31, 2025
Bay Colony Advisors
14.00K
0.13%
+14.00K
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
占比0%
iShares Russell 2000 ETF
占比0%
ProShares UltraPro Russell2000
占比0%
ProShares Hedge Replication ETF
占比0%
iShares Russell 2000 Growth ETF
占比0%
iShares Russell 2000 Value ETF
占比0%
Global X Russell 2000 ETF
占比0%
Proshares Ultra Russell 2000
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Nov 22, 2024
Merger
25<1
Nov 22, 2024
Merger
25<1
Nov 22, 2024
Merger
25<1
Nov 22, 2024
Merger
25<1
公告日期
类型
比率
Nov 22, 2024
Merger
25<1
Nov 22, 2024
Merger
25<1
Nov 22, 2024
Merger
25<1
Nov 22, 2024
Merger
25<1
